A retrospective analysis of discordances between international normalized ratio (INR) self-testing and INR laboratory testing in a pediatric patient population.
Anticoagulants
international normalized ratio
point-of-care systems
quality control
thromboplastin
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
29
05
2021
received:
06
04
2021
accepted:
21
06
2021
pubmed:
9
7
2021
medline:
15
12
2021
entrez:
8
7
2021
Statut:
ppublish
Résumé
The lack of quality control procedures for home point-of-care (POC) international normalized ratio (INR) devices is a concern. Concomitant laboratory and POC INR testing may be proposed to overcome the lack of quality control. However, a difference between the POC INR and the laboratory INR is not necessarily due to failure of the POC device. This study aimed to identify variables associated with a significant deviation between the POC INR and the laboratory INR. Children included in this retrospective cohort study performed at least one concomitant laboratory and POC INRs. Clinical and laboratory variables were assessed for an association with significant deviation within pairs of INR. A significant deviation was noted for 30 (15.3%) of the 196 pairs of INR measurements from 124 children. Relative to patients without deviations, patients with deviations were younger (odds ratio =0.91; P = .020), less experienced in the use of POC INR devices (odds ratio =0.89; P = .098), and more likely to have received an INR result from a laboratory using animal thromboplastin (odds ratio =2.81 vs. 0.37 for laboratories using human thromboplastin; P = .016). In a multivariate analysis, younger age and the laboratory's use of animal thromboplastin were associated with significant deviations. Although most children had coherent pairs of INR values, the occurrence of deviations raises the question of the origin of the thromboplastin used in the laboratory and emphasizes the need to provide specific quality control procedures for POC INR devices.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1575-1584Subventions
Organisme : Association pour la Recherche en Cardiologie du Fœtus à l'Adulte (ARCFA, Paris, France)
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Moon JR, Jeong SI, Huh J, Lee HJ, Park PW, Kang I-S. Accuracy of CoaguChek XS for point-of-care antithrombotic monitoring in children with heart disease. Ann Clin Lab Sci. 2010;40(3):247-251.
Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children. Chest. 2012;141(2 suppl):e737S-e801S.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133(6):160S-198S.
Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292-3316.
Heneghan CJ, Garcia-Alamino JM, Spencer EA, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;7(7).
Gadisseur APA, Breukink-Engbers WGM, van der Meer FJM, van den Besselaar AMH, Sturk A, Rosendaal FR. Comparison of the Quality of Oral Anticoagulant Therapy Through Patient Self-management and Management by Specialized Anticoagulation Clinics in the Netherlands: A Randomized Clinical Trial. Arch Intern Med. 2003;163(21):2639-2646.
Bauman ME, Massicotte MP, Kuhle S, Siddons S, Bruce A. EMPoWARed: Edmonton pediatric warfarin self-management study. Thromb Res. 2015;136(5):887-893.
Jones S, Newall F. Development of a home international normalized ratio monitoring program: strategic approach and evaluation. J Paediatr Child Health. 2013;49(9):E357-360.
Amedro P, Bajolle F, Bertet H, et al. Quality of life in children participating in a non-selective INR self-monitoring VKA-education programme. Arch Cardiovasc Dis. 2018;111(3):180-188.
Arrêté du 18 juin 2008 relatif à l’inscription du dispositif d’automesure de l’INR COAGUCHEK XS de la société Roche Diagnostics au chapitre 1er du titre Ier de la liste des produits et prestations remboursables prévue à l’article L. 165-1 du code de la sécurité sociale - Légifrance. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000019058107/. Accessed March 13, 2021
Arrêté du 28 juillet 2017 portant inscription dispositif d’auto-mesure de l’INR COAGUCHEK INRANGE de la société ROCHE DIAGNOSTICS au titre Ier de la liste des produits et prestations remboursables prévue à l’article L. 165-1 du code de la sécurité sociale - Légifrance. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000035329082/. Accessed March 13, 2021
Bajolle F, Lasne D, Elie C, et al. Home point-of-care international normalised ratio monitoring sustained by a non-selective educational program in children. Thromb Haemost. 2012;108(10):710-718.
Jespersen J, Poller L, van den Besselaar AMHP, et al. External quality assessment (EQA) for CoaguChek monitors. Thromb Haemost. 2010;103(5):936-941.
Poller L, Keown M, Ibrahim SA, et al. Quality Assessment of CoaguChek Point-of-Care Prothrombin Time Monitors: Comparison of the European Community-Approved Procedure and Conventional External Quality Assessment. Clin Chem. 2006;52(10):1843-1847.
Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2(6):849-860.
Kitchen S, Walker ID, Woods TAL, Preston FE. Thromboplastin related differences in the determination of international normalised ratio: a cause for concern? Thromb Haemost. 1994;72(09):426-429.
Biedermann JS, van den Besselaar AMHP, de Maat MPM, Leebeek FWG, Kruip MJHA. Monitoring of treatment with vitamin K antagonists: recombinant thromboplastins are more sensitive to factor VII than tissue-extract thromboplastins. J Thromb Haemost. 2017;15(3):500-506.
Smith SA, Comp PC, Morrissey JH. Phospholipid composition controls thromboplastin sensitivity to individual clotting factors. J Thromb Haemost. 2006;4(4):820-827.
Lasne D, Drouet L, Schved J-F, Gruel Y. GFHT proposals for management of discordance between the International normalized ratio measured in the laboratory and by self-testing. Ann Biol Clin (Paris). 2020;78(6):655-664.
Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children. Chest. 2008;133(6):887S-968S.
ISO 17593:2007. ISO. https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/standard/03/68/36872.html. Accessed March 13, 2021
Moreau C, Bajolle F, Siguret V, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119(3):861-867.
Takeuchi M, Kobayashi T, Biss T, et al. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. Pharmacogenomics J. 2020;20(2):306-319.
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239.
Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med. 1993;118(7):511-520.
Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet. 1986;327(8476):307-310.
Kitchen DP, Kitchen S, Jennings I, et al. Point of Care INR testing devices: performance of the Roche CoaguChek XS and XS Plus in the UK NEQAS BC external quality assessment programme for healthcare professionals: four years’ experience. J Clin Pathol. 2012;65(12):1119-1123.
Talboom-Kamp EPWA, Verdijk NA, Talboom IJSH, Harmans LM, Numans ME, Chavannes NH. PORTALS: design of an innovative approach to anticoagulation management through eHealth. BMC Health Serv Res. 2017;17:213.
Nagler M, Bachmann LM, Schmid P, Raddatz Müller P, Wuillemin WA. Patient self-management of oral anticoagulation with vitamin k antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. PLoS One. 2014;9(4):e95761.
Roussi J, Drouet L, Samama M, Sié P. French multicentric evaluation of recombinant tissue factor (recombiplastin) for determination of prothrombin time. Thromb Haemost. 1994;72(5):698-704.
Testa S, Morstabilini G, Fattorini A, Galli L, Denti N, D’Angelo A. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system. Haematologica. 2002;87(12):1265-1273.
Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood. 1999;94(9):3007-3014.
Jones S, Monagle P, Manias E, Bruce AAK, Newall F. Quality of life assessment in children commencing home INR self-testing. Thromb Res. 2013;132(1):37-43.
Palareti G, Manotti C, D’Angelo A, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost. 1997;78(6):1438-1443.
Cabalka AK, Emery RW, Petersen RJ, et al. Long-term follow-up of the St. Jude Medical prosthesis in pediatric patients. Ann Thorac Surg. 1995;60(6 Suppl):S618-623.
Sandén P, Renlund H, Svensson PJ, Själander A. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR. Thromb Haemost. 2017;26(1):27-32.
Meijer P, Kynde K, van den Besselaar AMHP, Blerk MV, Woods TAL. International normalized ratio (INR) testing in Europe: between-laboratory comparability of test results obtained by Quick and Owren reagents. Clin Chem Lab Med CCLM. 2018;56(10):1698-1703.